Akebia Therapeutics, Inc.
AKBA
$1.43
$0.010.70%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 92.30% | 65.42% | 9.79% | -5.30% | -33.67% |
| Total Depreciation and Amortization | -96.62% | -75.36% | -53.73% | -31.97% | -10.38% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 79.79% | 154.03% | 467.34% | 320.17% | 316.64% |
| Change in Net Operating Assets | 141.52% | 83.61% | 27.82% | -65.93% | -91.42% |
| Cash from Operations | 267.22% | 184.15% | 93.83% | -37.72% | -73.88% |
| Capital Expenditure | -781.82% | -619.35% | -410.34% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -23,918.18% | -64.52% | 182.76% | -- | -- |
| Total Debt Issued | -77.78% | -77.78% | -77.78% | -51.35% | -- |
| Total Debt Repaid | 88.61% | 98.98% | 98.98% | 98.42% | -15.93% |
| Issuance of Common Stock | 58.86% | 230.50% | 254.74% | 248.29% | 533.41% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 4.95% | 95.05% | 22.00% | 22.00% | -- |
| Cash from Financing | 46.84% | 284.29% | 302.85% | 1,049.21% | 297.03% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,382.48% | 1,160.93% | 792.51% | 545.28% | 118.46% |